Healthcare
Windlas Biotech Limited (windlas) Q1fy27: Revenue Streak Extends to 14 Quarters with 18% Yoy Growth
Windlas Biotech Limited (WINDLAS) reports Q1FY27 results with 18% YoY revenue growth to Rs 248 crore, EBITDA up 26%, and PAT up 37%.
Windlas Biotech Limited (WINDLAS) has started FY27 with a positive note by extending its record revenue streak to 14 consecutive quarters with an impressive 18% year-on-year growth to Rs 248 crore in Q1FY27. Consistent with its focus on long-term shareholders value creation, in Q1FY27 the company also completed a ₹47 crore buyback in which promoters did not participate and declared a FY26 dividend of ₹13 crore (₹6.30 per equity share).
Financial Highlights
Excluding the impact of Non-cash ESOP expenses (₹7.2 crore) which are non-cash in nature, our EBITDA grew 26% YoY to ₹34 crore, PBT and PAT grew 27% and 37% YoY to ₹30 crore and ₹25 crore respectively, reflecting our continued focus on improving operational leverage. If we take into account Non-cash ESOP expenditure (₹7.2 crore), the company reported EBITDA ₹27 crore, PBT ₹23 crore, and PAT ₹18 crore. For Q1FY27 Earnings Per Share (EPS) has improved to ₹8.46.
Vertical Performance
Our Generic Formulations CDMO vertical delivered 29% YoY revenue growth to ₹207 crore, driven by customer expansion, deeper customer engagement, and new product launches. The Trade Generics & Institutional vertical reported revenue of ₹30 crore, following the discontinuation of codeine-based products. As we expand the portfolio with new launches and replacements, we expect to progressively bridge the gap. Our Exports vertical recorded 79% YoY growth to ₹11 crore.
Looking ahead, our priorities remain focused on strengthening strategic partnerships, expanding our offerings, achieving operational excellence, accelerating portfolio development, and driving disciplined execution. Supported by a modernized manufacturing base, a talented workforce, and a clear strategic direction, we are well positioned to capitalize on the opportunities across all three business verticals.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Windlas Biotech Limited
Windlas Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Windlas moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 7.4% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The business compounds revenue at 20.7% and profits at 16.0% CAGR. That is strong double-digit growth on both counts. The stock holds at 46% of its 52-week range with RSI at 61. In other words, neither side has a clear edge right now. Revenue grows at 20.7% and profits at 16.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Windlas Biotech Limited.
Healthcare
Jagsonpal Pharmaceuticals Limited Acquires Wellness Portfolio of Group Pharmaceuticals
Jagsonpal Pharmaceuticals Ltd. acquires Wellness Portfolio of Group Pharmaceuticals, enhancing its pharmaceutical portfolio and market reach.
Jagsonpal Pharmaceuticals Limited (Jagsonpal) today announced the execution of a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited (Group Pharma) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves an initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of up to ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of conditions precedent and other terms stipulated under the BTA.
Strategic Growth Move
This acquisition marks another meaningful step in Jagsonpal’s growth journey. It strengthens the company’s pharmaceutical portfolio and expands its presence across complementary therapeutic segments, especially in women healthcare, while remaining consistent with its asset-light and focused approach to growth. Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: ‘The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.’
Seamless Integration
Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: ‘We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.’
The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA. Think Law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Jagsonpal posts a 0.9% three-month gain, but softens in the last few weeks. The PEG of 1.95 limits the upside. The stock does not come cheap. Revenue grows at 6.7% and profits at 17.3% CAGR. The numbers are respectable but unlikely to re-rate the stock. The stock gives back 3.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 0.9% in three months on 6.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Jagsonpal Pharmaceuticals Limited.
Health Information Services
Indegene Limited (indgn): from Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI
Indegene Limited (INDGN) highlights at Digital Summit 2026: Leaders focus on operationalizing AI for enterprise outcomes.
Indegene Limited (INDGN) recently hosted its eighth edition of the Digital Summit, focusing on operationalizing AI to deliver enterprise outcomes in the life sciences sector. The event, held on September 22 at the National Constitution Center in Philadelphia, brought together over 200 senior leaders to discuss translating AI investments into measurable business impact.
Operationalizing AI for Business Impact
The summit’s theme, ‘From Promise to Performance: Operationalizing AI for Enterprise Outcomes,’ emphasized the need for a next-generation operating model in life sciences. Speakers highlighted how AI can connect data, intelligence, and evidence to enable strategic decisions, drive successful product launches, and accelerate drug discovery and clinical research.
Recognition at VITAL Awards
The summit also hosted the second edition of the VITAL Awards, recognizing leaders delivering measurable industry impact. Honorees were named in Organizational Impact and Market Impact categories, alongside special awards for Transformational Leadership. Notable recipients included Brian Cantwell and Agam Upadhyay for Transformational Leadership, and Saket Malhotra for Organizational Impact.
Manish Gupta, Chairman and CEO of Indegene, remarked, ‘Life sciences has built an extraordinary legacy of helping people live longer, healthier lives. But increasingly specialized therapies and precision medicines cannot be supported by operating models designed for an era of mass promotion. The opportunity now is to thoughtfully rewire the enterprise around AI, augment our people, and build systems that are smarter, faster, and more responsive, turning the promise of technology into measurable performance for patients, physicians, and the business.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indegene Limited
Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.
Indegene gains 15.5% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 2.1x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 15.5% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.
GLENMARK
Glenmark Pharmaceuticals Limited Receives E Stablishment Inspection Report from U.S. FDA
Glenmark Pharmaceuticals Limited (GLENMARK) receives Establishment Inspection Report from U.S. FDA for its Goa facility with Voluntary Action Indicated status.
Glenmark Pharmaceuticals Limited (GLENMARK) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa, India, with a Voluntary Action Indicated (VAI) status. The inspection was conducted from June 22, 2026, to June 30, 2026. This report is a significant milestone for the company as it underscores the quality and compliance of its manufacturing processes.
Inspection Highlights
The U.S. FDA’s inspection team evaluated various aspects of the manufacturing facility, including production protocols, quality control measures, and overall facility management. Notably, the FDA highlighted areas that require voluntary actions to address certain observations. This VAI classification indicates that while the facility meets most regulatory standards, there are specific areas needing improvement.
Company’s Response
Glenmark Pharmaceuticals Limited is committed to addressing the observations mentioned in the report. The company plans to implement corrective and preventive actions to ensure full compliance with FDA standards. This proactive approach will help Glenmark maintain its reputation for high-quality pharmaceutical manufacturing.
As a result, Glenmark Pharmaceuticals Limited continues to focus on innovation and accessibility, aiming to deliver affordable and high-quality medicines globally. The company’s robust manufacturing infrastructure and commitment to excellence will drive its ongoing success and compliance with international regulatory standards.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Glenmark rises 12.9% over three months, with buying pressure holding steady. The PEG of 0.59 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 13.5% and profits at 66.1% CAGR. The market consistently rewards this kind of compounding. The stock trades at 90% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.59 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.
-
Basic Materials2 days agoEuro Pratik Sales Limited (europratik) to Acquire 56% Stake in Fab Wood, Expanding into Timber and Value-added Wood Products
-
Basic Materials3 days agoJindal Stainless Limited (JSL) Wins Dual Recognition at CII National Energy Management Awards 2026
-
Consumer Cyclical3 days agoLemon Tree Hotels Limited Expands in Maharashtra with 16 New Properties in Pipeline
-
Consumer Defensive3 days agoCupid Limited FY26: Revenue Up 93%, PAT Surges 165%
-
INTELLECT2 days agoIntellect Design Arena Limited Upgrades Cargills Bank’s Core Banking Architecture for the Next Decade
-
Solar3 days agoSolex Energy Limited (solex) Outlines Next Phase of Growth at 12th AGM, Targets ₹4,500 Crore Revenue Potential by FY28
-
RATEGAIN3 days agoRategain Travel Technologies Limited (NSE: Rategain) Honors Sylvia Weiler in 2026 Adexchanger Top Women in Media and Ad Tech Awards
-
Information Technology Services3 days agoPersistent Systems Limited Successfully Completes Takeover Offer for Nagarro